Groundbreaking Results from Novo Nordisk's REDEFINE 2 Trial
Today, Novo Nordisk unveiled exciting findings from a significant phase 3 trial, REDEFINE 2, focusing on CagriSema, a promising treatment aimed at adults grappling with obesity or overweight and type 2 diabetes. The study, which lasted 68 weeks, explored the efficacy and safety of once-weekly subcutaneous CagriSema, a combination of cagrilintide and semaglutide, against a placebo. A robust group of 1,206 participants, with an average starting weight of 102 kg, took part in this groundbreaking research.
Key Findings of the REDEFINE 2 Trial
The results of the REDEFINE 2 trial highlighted a remarkable and statistically significant weight loss associated with CagriSema when evaluated over the trial period. Specifically, the group receiving CagriSema achieved an impressive weight loss average of 15.7% at the end of the study. In stark contrast, the placebo group managed only 3.1% weight loss, demonstrating CagriSema's superior performance in this area.
Flexibility and Dosing in the Trial
One of the unique aspects of this trial was its flexible protocol, allowing participants to adjust their dosing as necessary. By the conclusion of the 68 weeks, around 61.9% of those treated with CagriSema were utilizing the highest dose available.
Weight Loss Goals Achieved
Among the treatment metrics, the goal of losing 5% or more of body weight was met by a striking 89.7% of the participants on CagriSema, while only 30.3% of those in the placebo group reached this milestone. This impressive result underscores the effectiveness of the CagriSema therapy.
Safety Profile and Adverse Events
The safety profile of CagriSema was another focal point of the trial. Most adverse effects observed were gastrointestinal, but they were primarily mild to moderate in severity and tended to decrease over time, aligning with the expected responses seen in the GLP-1 receptor agonist class.
Insights from Novo Nordisk Executives
Martin Holst Lange, executive vice president for Development at Novo Nordisk, expressed optimism regarding the REDEFINE 2 results, noting the superior efficacy of CagriSema in treating those with obesity or overweight coupled with type 2 diabetes. The company is eager to present these findings to regulatory authorities, aiming to provide this advanced therapy to millions of patients in need.
Future Prospects for CagriSema
Looking ahead, Novo Nordisk plans to pursue the first regulatory approval for CagriSema in early 2026. Detailed outcomes from both REDEFINE 1 and REDEFINE 2 trials are set to be unveiled at a major scientific conference in 2025, sparking anticipation within the medical community.
Explaining CagriSema
CagriSema is a once-weekly subcutaneous injection designed to address both obesity and type 2 diabetes through a combined dosage of cagrilintide and semaglutide. This innovative therapy works by suppressing appetite and promoting a sense of fullness, enabling users to eat less and thereby lower their daily calorie intake.
The REDEFINE Clinical Trial Programme
The REDEFINE clinical trial programme encompasses a series of pivotal phase 3 studies aimed at evaluating CagriSema's impact on obesity. In total, the program includes approximately 4,600 participants across various trials.
Overview of Trial Phases
The REDEFINE programme is composed of several key trials: REDEFINE 1 evaluated participants without type 2 diabetes, while REDEFINE 2 focused on those with type 2 diabetes and related weight issues. Further phases will continue to expand this valuable research to include cardiovascular outcomes and comparative studies with other obesity treatments.
About Novo Nordisk
Novo Nordisk stands as a pioneer in global healthcare, tracing its origins back to 1923. With a foundational commitment to combat chronic diseases, especially diabetes, the company has continually pushed boundaries in medical research. Novo Nordisk operates in 80 countries, providing life-altering medications to patients worldwide, including in markets that span roughly 170 countries. The company’s shares are prominently listed on the Nasdaq Copenhagen as Novo-B, with its American Depositary Receipts (ADRs) traded on the New York Stock Exchange as NVO.
Contact Information
For more details, interested parties can reach out to:
- Media Contact: Ambre James-Brown
Phone: +45 3079 9289
Email: ambre@novonordisk.com - Media Contact: Liz Skrbkova (US)
Phone: +1 609 917 0632
Email: lzsk@novonordisk.com - Investor Contact: Jacob Martin Wiborg Rode
Phone: +45 3075 5956
Email: jrde@novonordisk.com - Investor Contact: Sina Meyer
Phone: +45 3079 6656
Email: azey@novonordisk.com
Frequently Asked Questions
What is CagriSema?
CagriSema is a once-weekly injectable medication developed by Novo Nordisk to treat obesity and type 2 diabetes.
What were the main results from the REDEFINE 2 trial?
The REDEFINE 2 trial demonstrated significant weight loss in participants using CagriSema compared to those on a placebo.
How many people participated in the REDEFINE 2 trial?
A total of 1,206 individuals entered the REDEFINE 2 trial, all dealing with obesity or overweight and type 2 diabetes.
What is the future of CagriSema?
Novo Nordisk plans to file for regulatory approval in early 2026 and will present detailed trial results at a 2025 scientific conference.
What are the potential side effects of CagriSema?
Most side effects observed in the trial were mild to moderate gastrointestinal issues that improved over time.
